Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
2(33.3%)
Phase 4
2(33.3%)
Phase 3
2(33.3%)
6Total
Phase 2(2)
Phase 4(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06476210Phase 4Recruiting

The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)

Role: collaborator

NCT06305104Phase 2Recruiting

Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old.

Role: collaborator

NCT03027154Phase 3Completed

Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen for Children

Role: collaborator

NCT02623556Phase 3Completed

Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen

Role: collaborator

NCT02336542Phase 2Completed

Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10

Role: collaborator

NCT02901288Phase 4Unknown

Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis

Role: collaborator

All 6 trials loaded